CN Patent

CN108191913A — 一种替诺福韦艾拉酚胺晶型a及其制备方法

Assigned to Sichuan Haisco Pharmaceutical Co Ltd · Expires 2018-06-22 · 8y expired

What this patent protects

本发明涉及替诺福韦艾拉酚胺晶型a及其制备方法，包含该新固态形式的药物组合物，以及该新固态形式用于制备预防和/或治疗病毒感染，特别乙型肝炎病毒(HBV)和/或人类免疫缺陷病毒(HIV)感染的药物中的用途。

USPTO Abstract

本发明涉及替诺福韦艾拉酚胺晶型a及其制备方法，包含该新固态形式的药物组合物，以及该新固态形式用于制备预防和/或治疗病毒感染，特别乙型肝炎病毒(HBV)和/或人类免疫缺陷病毒(HIV)感染的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN108191913A
Jurisdiction
CN
Classification
—
Expires
2018-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.